Mabwell (Shanghai) Bioscience Co., Ltd.

Equities

688062

CNE100005RD2

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. 06:00:00 2024-05-14 pm EDT 5-day change 1st Jan Change
33.62 CNY -2.21% Intraday chart for Mabwell (Shanghai) Bioscience Co., Ltd. -3.67% +2.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821 CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mabwell Announces MAIWEIJIAN, First Approved Biosimilar of Denosumab in China CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mabwell Shanghai Bioscience Unit Gets Nod in China for Denosumab as Bone Tumor Treatment MT
Mabwell Presents Clinical Study Data of the 9MW2821 for Patients with Cervical Cancer as Focused Plenary Oral Presentation At the Society of Gynecologic Oncology Annual Meeting CI
Mabwell Scraps Licensing Deal With Yangtze River Pharma MT
Mabwell Publishes Phase III Study Results of Denosumab Biosimilar in the International Top Journal of Jama Oncology CI
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7Mw3711 CI
Mabwell Shanghai Bioscience Gets US FDA's Nod to Trial on Tumor Drug; Shares Jump 5% MT
Certain A-Shares of Mabwell Bioscience Co., Ltd. are subject to a Lock-Up Agreement Ending on 18-JAN-2024. CI
National Medical Products Administration Accepts Mabwell's 8MW0511 for Injection Accepted by NMPA CI
Mabwell Announces the Cde Approval of Novel Nectin-4 Targeting Adc for Phase III Clinical Trial CI
Mabwell Shanghai Bioscience Gets Nod to Trial Urothelial Cancer Drug MT
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor CI
Mabwell Bioscience Co., Ltd.(XSSC:688062) added to S&P Global BMI Index CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Mabwell Bioscience Co., Ltd. Announces the U.S. FDA approval of 9MW3811 for IND CI
Mabwell Shanghai Bioscience Gets Nod to Trial 9MW3811 Injection MT
Mabwell Shanghai Bioscience's Unit Gets Nod to Hold Trial into Tumor Drug MT
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Mabwell Shanghai Bioscience Publishes Positive Results from Cancer Drug MT
Mabwell Announces the Denosumab Solution for Injection Has Been Formed for Marketing by the National Medical Products Administration CI
Chart Mabwell (Shanghai) Bioscience Co., Ltd.
More charts
Mabwell Shanghai Bioscience Co Ltd is a China-based company mainly engaged in the research and development, production and sales of therapeutic biological products. The Company's main businesses include the establishment of new varieties of drugs and the discovery of some early projects, the organization and development of preclinical research and pharmacological effects, and the development of drugs for preclinical research. The Company is also engaged in the organization, management and development of clinical trials of research species. The Company's research on drugs covers autoimmune, tumor, metabolism, ophthalmology, infection and other disease fields. The Company conducts business in domestic and foreign markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
33.62 CNY
Average target price
39.92 CNY
Spread / Average Target
+18.72%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688062 Stock
  4. News Mabwell (Shanghai) Bioscience Co., Ltd.
  5. Mabwell Shanghai Bioscience Gets Nod to Trial Urothelial Cancer Drug
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW